Stay updated on TKI in Myeloid Hypereosinophilic Syndrome Clinical Trial
Sign up to get notified when there's something new on the TKI in Myeloid Hypereosinophilic Syndrome Clinical Trial page.

Latest updates to the TKI in Myeloid Hypereosinophilic Syndrome Clinical Trial page
- CheckyesterdayChange DetectedThe record describes imatinib and ruxolitinib treatment for hypereosinophilic syndrome, with updated study-arm details and eligibility information. It also now indicates that results are posted and lists measures of treatment response.SummaryDifference7%

- Check8 days agoChange DetectedThe page displays the ClinicalTrials.gov record for a hypereosinophilic syndrome study, including its treatments, eligibility criteria, outcomes, and history, instead of a 403 Forbidden screen.SummaryDifference50%

- Check15 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov release as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check22 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision changes from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe 403 error page’s footer revision changes from v3.7.0 to v3.7.1; the page otherwise remains an error page.SummaryDifference0.2%

Stay in the know with updates to TKI in Myeloid Hypereosinophilic Syndrome Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TKI in Myeloid Hypereosinophilic Syndrome Clinical Trial page.